Exact Sciences Corporation (NASDAQ:EXAS) is reporting third quarter financial results on Thursday 29th October 2020, after market close.
According to analysts surveyed by Thomson Reuters, EXAS is expected to report 3Q20 loss of $ 0.39 per share from revenue of $ 418.59 million.
For the full year, analysts anticipate top line of $ 1426.56 million, while looking forward to loss of $ 2.4 per share bottom line.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 1,610.00 million ~ $ 1,645.00 million
Click Here For More Historical Outlooks Of Exact Sciences Corporation
Previous Quarter Performance
Exact Sciences Corporation outlined loss for the second quarter of $ 0.58 per share, from the revenue of $ 268.87 million. The quarterly revenues boosted 47.62 percent compared with the same quarter last year. The consensus estimates are loss of $ 0.63 per share from $ 228.42 million in revenue. The bottom line results beat street analysts by $ 0.05 or 7.94 percent, at the same time, top line results outshined analysts by $ 40.45 million or 17.71 percent.
Stock Performance
Shares of Exact Sciences Corporation traded low $ -3.60 or -2.75 percent on Wednesday, reaching $ 127.52 with volume of 4.64 million shares. Exact Sciences Corporation has traded high as $ 135.00 and has cracked $ 124.91 on the downward trend
According to the previous trading day, closing price of $ 127.52, representing a 271.97 % increase from the 52 week low of $ 35.25 and a 7.6 % decrease over the 52 week high of $ 141.90.
The company has a market capital of $ 19.18 billion and is part of the Healthcare sector and Diagnostics & Research industry.
Recent Analyst recommendations
- On 25th September 2020, maintained by Canaccord Genuity at Buy rating, with $ 120.00 target price.
Conference Call
Exact Sciences Corporation will be hosting a conference call at 5:00 PM eastern time on 29th October 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.exactsciences.com
Exact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States. The company offers Cologuard, a non-invasive stool-based DNA screening test for the early detection of colorectal cancer and pre-cancer. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc.
